Andre the Giant and Acromegaly: The Evidence Base Behind Growth Hormone Excess

Who Was Andre the Giant and What Likely Caused His Size?

Andre Rene Roussimoff was born May 19, 1946, in Coulommiers, France. By his teenage years he stood well over six feet and continued growing into his twenties, a pattern inconsistent with constitutional tall stature. Andre reportedly told interviewers he had been told by doctors that he had a glandular condition, though no medical records have been published. Clinicians who have reviewed his photographs and documented history almost uniformly describe a presentation consistent with acromegaly from a GH-secreting pituitary adenoma active from childhood into adulthood.

The Difference Between Gigantism and Acromegaly

Timing matters enormously in growth hormone excess. When a pituitary adenoma secretes excess GH before epiphyseal growth plate closure, the result is gigantism: vertical growth continues well beyond normal limits. When excess GH appears after growth plate fusion, the result is acromegaly, characterized by soft-tissue swelling, jaw enlargement (prognathism), hand and foot enlargement, and visceral organ growth rather than dramatic height gain.

Andre's case likely involved both phases. His extreme height suggests GH excess began in childhood or early adolescence, before plate closure. His progressive facial coarsening, jaw enlargement, and hand size documented across his wrestling career photographs suggest ongoing GH excess well into adulthood, consistent with active acromegaly layered on top of earlier gigantism. The Endocrine Society's 2014 clinical practice guideline on acromegaly explicitly identifies this combined presentation as a recognized phenotype.

Why Andre Never Received Treatment

Andre spent his professional life in the 1970s and 1980s, when transsphenoidal surgery was less refined and somatostatin analogues had only recently entered clinical use. Octreotide received FDA approval in 1988, just five years before Andre's death. Beyond timing, access and motivation likely played roles. Professional wrestling depended on his extraordinary size. There is no documented evidence he sought or received treatment for a pituitary tumor during his lifetime.

The Pathophysiology of GH-Secreting Pituitary Adenomas

Growth hormone excess in acromegaly originates in roughly 95% of cases from a benign pituitary adenoma, with somatotroph adenomas accounting for the large majority. These tumors secrete GH autonomously, bypassing the normal hypothalamic-pituitary feedback loop. A 2019 review in the New England Journal of Medicine summarized the molecular pathogenesis: approximately 40% of somatotroph adenomas carry activating mutations in the GNAS gene (encoding the alpha subunit of the stimulatory G protein), which constitutively activates adenylyl cyclase and drives unregulated GH secretion.

GH and IGF-1: The Two Biochemical Drivers

Excess pituitary GH stimulates the liver to produce insulin-like growth factor 1 (IGF-1). IGF-1 is the primary mediator of most tissue-growth effects. Both molecules are diagnostic targets.

GH itself is pulsatile and difficult to interpret from a single draw. The standard diagnostic test is an oral glucose tolerance test (OGTT): 75 g of glucose should suppress GH to below 1 ng/mL in healthy individuals. Failure to suppress confirms autonomous secretion. IGF-1, by contrast, is stable in serum and age- and sex-adjusted, making it the preferred screening tool. The 2014 Endocrine Society guideline states: "We recommend measuring serum IGF-1 to screen for acromegaly in patients with typical clinical features of the disease."

Systemic Consequences of Untreated Acromegaly

The metabolic and cardiovascular burden of uncontrolled GH excess is substantial. A meta-analysis of 16 studies published in the European Journal of Endocrinology found standardized mortality ratios between 1.3 and 2.5 in untreated acromegaly cohorts, with cardiovascular disease accounting for the largest share of excess deaths. Specific consequences include:

• Left ventricular hypertrophy (present in up to 80% of patients at diagnosis)
• Sleep apnea (affects 60-80% of acromegaly patients, partly from macroglossia and pharyngeal soft-tissue growth)
• Type 2 diabetes or impaired glucose tolerance (present in 20-56% of patients at diagnosis)
• Colon polyps and modestly elevated colorectal cancer risk
• Arthropathy from periarticular soft-tissue overgrowth

Andre reported severe arthritis and joint problems throughout his career, requiring substantial alcohol consumption he publicly described as pain management. His cardiovascular death at 46 is consistent with the excess mortality documented in population studies of acromegaly. A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that normalization of GH and IGF-1 reduces mortality to near-population levels, underscoring what untreated disease costs.

The Modern Treatment Protocol Andre Never Received

First-Line: Transsphenoidal Surgery

Surgical resection of the pituitary adenoma is the recommended first-line treatment in nearly all patients with acromegaly. The preferred approach is transsphenoidal surgery (through the nasal cavity and sphenoid sinus), now performed endoscopically at experienced centers. The 2014 Endocrine Society guideline recommends surgery as first-line therapy for most patients, with the goal of biochemical remission defined as a normal age-adjusted IGF-1 and a nadir GH below 1 ng/mL on OGTT.

Remission rates depend heavily on tumor size and invasiveness:

• Microadenomas (diameter <10 mm): remission in approximately 75-85% of cases at experienced centers
• Macroadenomas (diameter 10 mm or greater): remission in roughly 40-60%
• Invasive macroadenomas with cavernous sinus involvement: remission in 10-40%, requiring adjuvant therapy

A 2017 systematic review in Pituitary analyzed outcomes from 88 surgical series and confirmed these figures across 6,695 patients, with complication rates (diabetes insipidus, CSF leak, hypopituitarism) well under 5% at high-volume centers.

Andre's adenoma, given the severity and duration of his disease, was almost certainly a large macroadenoma or an invasive tumor by the time he reached adulthood. Surgical cure alone would have been unlikely. He would have needed adjuvant medical therapy.

Second-Line: Somatostatin Receptor Ligands

Somatostatin receptor ligands (SRLs) bind somatostatin receptors on somatotroph tumor cells, suppressing GH secretion. The two primary agents are:

Octreotide LAR (long-acting release): 10-40 mg intramuscularly every 28 days. In a key 6-month trial of 151 acromegaly patients with persistent disease after surgery, octreotide LAR normalized IGF-1 in 67% and achieved GH below 2.5 ng/mL in 74%. The landmark multicenter trial is summarized in JCEM.

Lanreotide autogel: 60-120 mg subcutaneously every 28 days. The PRIMARYS trial (N=90), published in JCEM in 2014, used lanreotide as primary therapy (before surgery) in newly diagnosed patients and achieved biochemical control in 34.6% at 48 weeks. Tumor volume shrank by at least 20% in 63.3% of patients, a clinically meaningful shrinkage rate that supports primary medical therapy in patients who are poor surgical candidates.

SRL therapy also addresses one of Andre's documented problems. Sleep apnea, which he likely had given his macroglossia and pharyngeal anatomy, responds to SRL-induced reduction in soft-tissue GH effects. A 2001 study in JCEM found octreotide reduced apnea-hypopnea index by 50% in acromegaly patients with obstructive sleep apnea, independent of weight change.

Third-Line: Pegvisomant

Pegvisomant is a GH receptor antagonist, not a somatostatin analogue. It blocks the GH receptor directly, preventing IGF-1 generation regardless of pituitary tumor activity. For patients with biochemically uncontrolled disease despite SRL therapy, pegvisomant normalizes IGF-1 in over 90% of cases. A 2007 observational study of 1,288 patients in ACROSTUDY, published in the European Journal of Endocrinology, confirmed this response rate in real-world practice.

Pegvisomant does not shrink the pituitary tumor and requires monitoring of tumor size and liver enzymes. It is typically used as monotherapy for SRL non-responders or combined with an SRL for partial responders.

Radiation: A Last Resort

Stereotactic radiosurgery (Gamma Knife or CyberKnife) is reserved for patients with residual tumor after surgery who cannot achieve biochemical control on medical therapy. Biochemical remission from radiation occurs slowly, typically over 3-10 years, and hypopituitarism develops in 30-50% of patients by 10 years. A 2016 systematic review in Neurosurgery reported GH normalization in 44% and IGF-1 normalization in 42% at 5 years after Gamma Knife, with latency limiting its utility as primary therapy.

Diagnosing Acromegaly: What the Evidence Supports Today

Clinical Recognition

The median delay from symptom onset to diagnosis of acromegaly is 7-10 years in modern cohort studies. A 2018 multicenter registry study (N=3,173) published by the European Acromegaly Survey found the mean diagnostic delay was 8.4 years, driven by the insidious onset of symptoms and their frequent misattribution to aging or obesity. In Andre's era, without modern imaging and with fewer physicians familiar with the syndrome, diagnosis would have been even less likely unless symptoms became severe enough to prompt specialist referral.

Clinical features that should prompt biochemical screening include:

• Progressive jaw enlargement or change in dental occlusion
• Increasing shoe, glove, or ring size in an adult
• Facial coarsening with prominent supraorbital ridges
• Hyperhidrosis and oily skin
• New-onset carpal tunnel syndrome (bilateral)
• Unexplained diabetes or hypertension in a young adult
• Headaches with or without visual field deficits

Imaging

Once biochemical diagnosis is confirmed, MRI of the pituitary with and without gadolinium contrast is the standard imaging modality. CT is an alternative when MRI is contraindicated. Somatostatin receptor scintigraphy (Octreoscan) or 68Ga-DOTATATE PET/CT may be used for ectopic GH or GHRH secretion, which accounts for under 5% of acromegaly cases.

A Practical Diagnostic Framework for Clinicians

The following three-step pathway reflects current guideline recommendations from the Endocrine Society and the European Society of Endocrinology:

Step 1. Screen: Measure serum IGF-1 (age- and sex-adjusted). An elevated IGF-1 in the absence of pregnancy, adolescence, or hepatitis requires confirmation.

Step 2. Confirm: Perform a 75 g OGTT with GH measured at 0, 30, 60, 90, and 120 minutes. GH nadir above 1 ng/mL confirms autonomous secretion. If IGF-1 is elevated and OGTT is equivocal, a GH profile (5-point day curve) may help.

Step 3. Localize: Order pituitary MRI with gadolinium. If MRI is negative, measure serum GHRH and consider chest/abdominal CT to exclude ectopic source.

Andre the Giant's Skeletal and Cardiovascular Profile: Clinical Interpretation

Skeletal Consequences

Andre's hands measured roughly 15 inches from wrist to fingertip, and his ring size was reportedly 24. These measurements far exceed constitutional gigantism alone. Ongoing acromelgaly causes periosteal bone apposition (new bone deposited on existing cortical bone) rather than endochondral growth, enlarging the jaw, orbital ridges, hands, feet, and rib cage even after epiphyseal closure. A 1994 review in Endocrine Reviews described this dual mechanism: early excess GH drives long-bone growth, while persistent adult excess drives periosteal expansion, explaining why acromegaly patients do not simply look like very tall people but have a distinctive morphology.

The arthropathy that contributed to Andre's disability arises from two mechanisms. Periarticular soft-tissue overgrowth narrows joint spaces, and excess GH directly stimulates cartilage proliferation in a disordered pattern. By his early 40s, Andre reportedly required crutches at times and struggled with basic mobility, a trajectory consistent with advanced acromegalic arthropathy.

Cardiovascular Risk

Acromegalic cardiomyopathy has a specific phenotype: concentric left ventricular hypertrophy initially, then eccentric hypertrophy and diastolic dysfunction, and finally systolic heart failure if GH excess persists for decades. A comprehensive review in Circulation described this progression and noted that normalization of GH and IGF-1 can partially reverse early cardiomyopathic changes, though prolonged disease leaves irreversible fibrosis. Andre died of congestive heart failure at 46, a cause and age that align closely with the expected cardiovascular trajectory of decades of untreated, severe GH excess.

What Modern Medicine Would Offer a Patient Like Andre Today

A patient presenting today with Andre's apparent phenotype, a young adult with extreme tall stature, progressive acromegalic features, and active disease, would follow a defined pathway:

1. Serum IGF-1 (likely markedly elevated, potentially three to five times the upper limit of normal)
2. Confirmatory OGTT showing failed GH suppression
3. Pituitary MRI, very likely showing a large adenoma or invasive macroadenoma
4. Ophthalmology referral to assess visual field defects from optic chiasm compression
5. Transsphenoidal surgical resection at a high-volume pituitary center
6. Postoperative biochemical reassessment at 12 weeks
7. Adjuvant octreotide LAR or lanreotide for residual disease
8. Pegvisomant added or substituted if IGF-1 normalization is not achieved on SRL monotherapy
9. Annual pituitary MRI for tumor surveillance

The Endocrine Society guideline states: "The goals of treatment of acromegaly are to eliminate excess GH and IGF-1 production and to relieve or prevent complications from the tumor mass." With modern therapy started in early adulthood, the approximately 10-year reduction in life expectancy associated with untreated acromegaly becomes largely preventable. A 2020 JCEM study (N=3,344) confirmed that patients who achieve biochemical remission have mortality rates indistinguishable from the general population.

Andre the Giant's case is a stark illustration of that gap. Untreated for his entire life, he died at 46. With the tools available today, including transsphenoidal surgery, somatostatin analogues, and pegvisomant, he would have had a reasonable chance at a normal lifespan.